June 2011

TABLE OF CONTENTS

When Deals Work – & When They Don’t: Large Pharma Strategies for Off-Loading Shuttered Capacity

Derek G. Hennecke continues with part 3 of his newest 6-part series on how not to blow the recovery!

 

Numbers That Define the Business of Drug Delivery – 2011 Edition

Josef Bossart, PhD, believes that with the recent release of DDEP2011, it’s time to take a peek at the numbers that define the business of Drug Delivery, which provide a foundation to better plans and outcomes in the real world of drug delivery development and commercialization.

 

Diabetes Management: Injecting the End-User’s Perspective

Industry Analyst Misty Hughes summarizes part of a Frost & Sullivan customer research survey of type 2 diabetes patients to assess their awareness of insulin injection pen brands and measure current usage of insulin injection pens.

 

Viaskin^®: Epicutaneous Immunotherapy for Treating Food Allergies

Lucie Mondoulet, PhD; Nathalie Donne, MSc; and Pierre-Henri Benhamou, MD; review the VIASKIN epicutaneous patch and how it can desensitize against peanuts, milk, and other major food allergies with significant reduction in anaphylaxis risk.

 

Outsourcing Formulation Development: A Continuum on the Road to Drug Development

Contributor Cindy H. Dubin hosts a roundtable discussion with some of the industry’s top contract formulation developers to find out how they are working with pharma to overcome solubility issues and bioavailability challenges to get drugs to market faster.

 

Sustained Delivery to the Oral Tissues

Jerry Gin, PhD, MBA, says ingredients must be in contact with the tissues for a sufficient length of time to be effective for treating conditions in the mouth, and the SuRe^TM matrix delivery technology in the form of a long-lasting lozenge has been developed to accomplish this task.

 

Aptalis: Maximizing Drug Delivery Technologies in Today’s Pharmaceutical Environment

Drug Development Executive: Mr. John Fraher, President of Aptalis Pharma, discusses the increasingly important role of drug delivery technologies for today’s pharmaceutical marketplace.

 

Beyond Monoclonals for Severe Autoimmune Diseases

Guy-Charles Fanneau de la Horie and Pierre Vandepapeliere explain how Kinoids involve the administration of the target cytokine by intramuscular injection, formulated in such a way as to stimulate the patient’s own immune system to generate antibodies directed against the target cytokine.

 

What Are the Transformational Changes Required in the Big “R”?

Rosemarie Truman, PhD, addresses the transformational changes required, first and foremost, in Research, and how this function can better contribute to driving long-term innovation.

 

GeoVax Labs: Developing Preventative & Therapeutic HIV/AIDS Vaccines

Executive Summary: Dr. Robert T. McNally, President and CEO of GeoVax, talks about the advances his company is making in its development of a preventative and a therapeutic HIV/AIDS vaccine, and why it has the potential to play a significant role in combating one of the most devastating global epidemics.

 

DEPARTMENTS

 

Market News & Trends

 

Advanced Delivery Devices

Human Factors: The Drug Delivery Challenge & Opportunity

 

Technology & Services Showcase

 

External Delivery

COVER

FEATURES